Skip Content
You are currently on the new version of our website. Access the old version .
Current OncologyCurrent Oncology
  • Case Report
  • Open Access

29 June 2022

Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation

,
,
,
,
and
1
Department of Pathology, University of Maryland Medical System, Baltimore, MD 21201, USA
2
Department of Medicine, The George Washington University, Washington, DC 20037, USA
3
Department of Pathology, The George Washington University, Washington, DC 20037, USA
4
Department of Pathology, Veterans Health Administration Medical Center, Washington, DC 20422, USA
This article belongs to the Special Issue The Molecular Pathology of Myelodysplastic Syndromes

Abstract

Myelodysplastic syndromes (MDS) and Waldenstrom’s macroglobulinemia (WM) are rarely synchronous. Ineffective myelopoiesis/hematopoiesis with clonal unilineage or multilineage dysplasia and cytopenias characterize MDS. Despite a myeloid origin, MDS can sometimes lead to decreased production, abnormal apoptosis or dysmaturation of B cells, and the development of lymphoma. WM includes bone marrow involvement by lymphoplasmacytic lymphoma (LPL) secreting monoclonal immunoglobulin M (IgM) with somatic mutation (L265P) of myeloid differentiation primary response 88 gene (MYD88) in 80–90%, or various mutations of C-terminal domain of the C-X-C chemokine receptor type 4 (CXCR4) gene in 20–40% of cases. A unique, progressive case of concurrent MDS and WM with several somatic mutations (some unreported before) and a novel balanced reciprocal translocation between chromosomes 10 and 13 is presented below.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.